Levomilnacipran

Levomilnacipran

Clinical data
Trade names	Fetzima
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	By mouth (capsules)
ATC code	None
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	92%
Protein binding	22%
Metabolism	Hepatic (primarily by CYP3A4)
Biological half-life	12 hours
Excretion	Renal
Identifiers
IUPAC name (1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
CAS Number	96847-55-1 Y
PubChem CID	6917779
IUPHAR/BPS	7435
ChemSpider	5293005 N
UNII	UGM0326TXX
KEGG	D10072 N
Chemical and physical data
Formula	C15H22N2O
Molar mass	246.348 g/mol
3D model (Jmol)	Interactive image
SMILES CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
InChI InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1 N Key:GJJFMKBJSRMPLA-DZGCQCFKSA-N N
NY (what is this?)

Levomilnacipran (brand name Fetzima) is an antidepressant approved in the United States for the treatment of major depressive disorder (MDD) in adults. It was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the Food and Drug Administration in July 2013. Levomilnacipran is the levo- enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor (SNRI).

The FDA approved levomilnacipran in July 2013 based on the results of one 10-week phase II and four 8-week phase III clinical trials. Four of the five trials demonstrated a statistically significant superiority to placebo as measured by the Montgomery–Åsberg Depression Rating Scale. Superiority to placebo was also demonstrated by improvement in the Sheehan Disability Scale. Side effects seen more often than with placebo included nausea, dizziness, sweating, constipation, insomnia, increased heart rate and blood pressure, urinary hesitancy, erectile dysfunction and delayed ejaculation in males, vomiting, tachycardia, and palpitations.